Does Tuberculosis Risk Differ Among TNF Inhibitors?


Reactivation of latent tuberculosis is a recognized risk of TNF inhibitor use.  While there has been circumstantial evidence of greater risk with the monoclonal antibody TNF inhibitors (e.g. infliximab and adalimumab) compared with decoy receptor TNF inhibitors (e.g. etanercept), there have been few direct comparisons.  Here, Dixon et al (Ann Rheum Dis 2010; 69: 522-528) […]